1.Date of occurrence of the event:2021/03/13

2.Company name:Microbio (Shanghai) Co., Ltd.

3.Relationship to the Company (please enter ”head office” or

  ”subsidiaries”):Subsidiary

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

(1)New drug name or code:ON101

(2)Purpose: For the treatment of diabetic foot ulcers (DFU)

(3)Planned development stages：New drug application (NDA)

(4)Current development stage:

   A.File application:The Center for Drug Evaluation (CDE) under National

     Medical Products Administration (NMPA) accepted the new drug

     registration application for ON101, diabetic foot ulcer new drug.

   B.Once disapproved by competent authority or each of clinical trials

     (include interim analysis) results less than statistically significant

     sense, therisks & the associated measures the Company may occur: NA

   C.After obtaining official approval or the results of statistically

     significant sense, the future strategy: NA

   D.Accumulated investment expenditure incurred:No disclosure of the

     investment expenditure at the moment in consideration of the future

     marketing strategies to protect the company and investors interests.

(5)Upcoming development plan:

   A.Scheduled completion date: NA

   B.Estimate responsibilities: NA

(6)Market:

   DFU is the major complication of diabetes mellitus that imposes the hugest

   medical burden According to the national cross sectional study published

   on BMJ (BMJ 2020;369:m997), the prevalence of diabetes mellitus is 12.8%

   with an estimate of 130 million of adult DM patients. The systematic

   review and meta-analysis by Drum Tower Hospital Affiliated to Nanjing

   University Medical School showed that the prevalence of diabetic foot

   ulcer in China has reached 5.7%, which means there are more than 7.4

   million DFU patients in China. In addition, the 7-year retrospective

   review article published in Diabetes Metab Syndr Obes. 2020 demonstrated

   that the number of DFU patients increased along with that of DM patients

   impacting the national or regional healthcare worldwide financially.

   These have reflected not only the enormous medical burden imposed by DFUs

   , but also its impact on the patients and their family as a public health

   issue in need of effective new drugs urgently.

6.Countermeasures:None

7.Any other matters that need to be specified:

(1)ON101, diabetic foot ulcer new drug developed by Oneness Biotech has been

   out-licensed to Microbio (Shanghai) for commercialization exclusively in

   mainland China, Hong Kong, and Macau.

(2)According to Article 2 under Guidelines by Taipei Exchange on the Material

   Information Announced by Listed and OTC Companies, new drug development

   companies shall make public announcement when filing application for

   clinical trials and new drug registration to domestic or overseas

   regulatory authorities, receiving approval or disapproval, obtaining the

   statistical date of endpoints in each clinical trial (including interim

   analysis), or receiving approval or disapproval on drug license

   application.

(3)It takes considerable time and expenses to develop a new drug of which

   success can’t be guaranteed. Investors shall bear such investment risk